These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 11295953)
1. Primary prevention of coronary heart disease: where do we go from here? Gotto AM Arch Intern Med; 2001 Apr; 161(7):922-4. PubMed ID: 11295953 [No Abstract] [Full Text] [Related]
3. Dyslipidemia and coronary heart disease: management issues from Indian perspective. Gambhir DS; Gambhir JK; Sudha R Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772 [No Abstract] [Full Text] [Related]
4. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)? Sherrod JP; Krist A J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006 [No Abstract] [Full Text] [Related]
5. A symposium: lipid management summit on improving practice outcome. Introduction. Ballantyne CM Am J Cardiol; 2000 Feb; 85(3A):1A-2A. PubMed ID: 10695700 [No Abstract] [Full Text] [Related]
9. [Overviews of fibrate]. Tada N Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141 [No Abstract] [Full Text] [Related]
10. Reducing major vascular events among VA primary care patients: an extraordinary opportunity. Hammermeister K; Gethoffer H Clin Cornerstone; 2003; Suppl 1():S2-10. PubMed ID: 14699986 [TBL] [Abstract][Full Text] [Related]
11. Lipids in women: screening and treatment. Walsh JM J Am Med Womens Assoc (1972); 2003; 58(4):240-7. PubMed ID: 14640255 [TBL] [Abstract][Full Text] [Related]
13. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate]. Dobordzhginidze LM Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838 [No Abstract] [Full Text] [Related]
14. Lipids and prevention in coronary care. Betteridge DJ Trans Med Soc Lond; 1994-1995; 111():43-58. PubMed ID: 9156156 [No Abstract] [Full Text] [Related]
15. Correction to the FIELD study report. Keech A; Simes J; Barter P; Best J; Scott R; Taskinen MR; Lancet; 2006 Oct; 368(9545):1415. PubMed ID: 17055933 [No Abstract] [Full Text] [Related]
16. Applicability of cholesterol-lowering primary prevention trials to a general population: the framingham heart study. Lloyd-Jones DM; O'Donnell CJ; D'Agostino RB; Massaro J; Silbershatz H; Wilson PW Arch Intern Med; 2001 Apr; 161(7):949-54. PubMed ID: 11295957 [TBL] [Abstract][Full Text] [Related]
17. Implications of 4S evidence on baseline lipid levels. Jacobson TA Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245 [No Abstract] [Full Text] [Related]